NO20034740L - Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser - Google Patents

Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser

Info

Publication number
NO20034740L
NO20034740L NO20034740A NO20034740A NO20034740L NO 20034740 L NO20034740 L NO 20034740L NO 20034740 A NO20034740 A NO 20034740A NO 20034740 A NO20034740 A NO 20034740A NO 20034740 L NO20034740 L NO 20034740L
Authority
NO
Norway
Prior art keywords
galantamine
poisoning
treatment
nervous system
central nervous
Prior art date
Application number
NO20034740A
Other languages
English (en)
Other versions
NO20034740D0 (no
Inventor
Klaus Opitz
Joachim Moormann
Thomas Hille
Frank Becher
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20034740(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of NO20034740L publication Critical patent/NO20034740L/no
Publication of NO20034740D0 publication Critical patent/NO20034740D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20034740A 2001-04-24 2003-10-23 Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser NO20034740D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119862A DE10119862A1 (de) 2001-04-24 2001-04-24 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de) 2001-04-24 2002-04-18 Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (2)

Publication Number Publication Date
NO20034740L true NO20034740L (no) 2003-10-23
NO20034740D0 NO20034740D0 (no) 2003-10-23

Family

ID=7682409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034740A NO20034740D0 (no) 2001-04-24 2003-10-23 Anvendelse av galantamin for behandling av patologiske manifestasjoner i sentralnervesystemet grunnet forgiftning med psykotropiskesubstanser

Country Status (26)

Country Link
US (1) US8207159B2 (no)
EP (1) EP1383507B1 (no)
JP (1) JP2004531533A (no)
KR (1) KR20040005934A (no)
CN (1) CN100400043C (no)
AR (1) AR033468A1 (no)
AT (1) ATE378052T1 (no)
AU (1) AU2002308148B2 (no)
BR (1) BR0209126A (no)
CA (1) CA2444818C (no)
CZ (1) CZ20032789A3 (no)
DE (2) DE10119862A1 (no)
DK (1) DK1383507T3 (no)
EA (1) EA200301135A1 (no)
ES (1) ES2296990T3 (no)
HU (1) HUP0401123A3 (no)
IL (2) IL158382A0 (no)
MX (1) MXPA03009765A (no)
NO (1) NO20034740D0 (no)
NZ (1) NZ529004A (no)
PL (1) PL207525B1 (no)
PT (1) PT1383507E (no)
SK (1) SK287235B6 (no)
TW (1) TWI329512B (no)
WO (1) WO2002085370A1 (no)
ZA (1) ZA200308004B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr) 2008-05-06 2010-09-24 Biocodex Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1193061B (de) 1961-12-20 1965-05-20 Vni Chimiko Pharmazewtitschesk Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3843239C1 (no) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5015645A (en) * 1989-10-19 1991-05-14 Ciba-Geigy Corporation Tetracyclic pyrrole lactam derivatives
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de) 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

Also Published As

Publication number Publication date
DE50211207D1 (de) 2007-12-27
DK1383507T3 (da) 2008-03-17
AR033468A1 (es) 2003-12-17
ES2296990T3 (es) 2008-05-01
ZA200308004B (en) 2004-02-11
HUP0401123A2 (hu) 2004-09-28
NO20034740D0 (no) 2003-10-23
JP2004531533A (ja) 2004-10-14
WO2002085370A1 (de) 2002-10-31
BR0209126A (pt) 2004-07-27
ATE378052T1 (de) 2007-11-15
CN100400043C (zh) 2008-07-09
HK1062401A1 (zh) 2004-11-05
EP1383507B1 (de) 2007-11-14
CA2444818C (en) 2009-06-16
EP1383507A1 (de) 2004-01-28
HUP0401123A3 (en) 2008-01-28
PT1383507E (pt) 2008-02-20
CA2444818A1 (en) 2002-10-31
SK287235B6 (sk) 2010-04-07
CN1505516A (zh) 2004-06-16
US20040116406A1 (en) 2004-06-17
CZ20032789A3 (en) 2004-05-12
US8207159B2 (en) 2012-06-26
IL158382A0 (en) 2004-05-12
EA200301135A1 (ru) 2004-04-29
KR20040005934A (ko) 2004-01-16
SK13152003A3 (sk) 2004-04-06
MXPA03009765A (es) 2005-04-19
NZ529004A (en) 2007-01-26
AU2002308148B2 (en) 2006-11-02
PL207525B1 (pl) 2010-12-31
TWI329512B (en) 2010-09-01
IL158382A (en) 2009-09-01
DE10119862A1 (de) 2002-11-07
PL366840A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
NO20022585L (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet
EP1727530A4 (en) TOPICAL FORMULATIONS FOR THE TREATMENT OF SKIN DISEASES
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20021845D0 (no) Behandling av sövnforstyrrelser under anvendelse av desloratadin
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
EE200200571A (et) Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
IS6137A (is) Meðhöndlun á hugsýkistruflunum
NO20030295L (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
DE60033604D1 (de) Wärmebehandlung zur Verbesserung der Eigenschaften von Alpha-Beta-Titan-Legierungen
EE200200511A (et) Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks
PT1152756E (pt) Derivados de anticonvulsivo uteis no tratamento do autismo
NO20023803D0 (no) Anvendelse av mirtazapin for behandling av sövnforstyrrelser
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
EP1675549A4 (en) NKT-DRIVEN CELLS AND USES THEREOF IN THE TREATMENT OF IMMUNITY-RELATED DISORDERS
NO20034741D0 (no) Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser
DK1383507T3 (da) Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser
EE200100527A (et) Osanetandi kasutamine meeleoluhäirete raviks kasulike ravimite valmistamiseks
NO20024331D0 (no) Behandling av lidelser relatert til det serotonerge system
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
EP1973398A4 (en) USE OF INOSITE TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES
DE69934336D1 (de) Verwendung von halofuginone zur behandlung von urethralstriktur

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application